U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H22N2
Molecular Weight 266.3807
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYCLIZINE

SMILES

CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=UVKZSORBKUEBAZ-UHFFFAOYSA-N
InChI=1S/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3

HIDE SMILES / InChI

Description

Cyclizine (cyclizine hydrochloride, Valoid®) is a histamine H1 antagonist of the piperazine class which is characterised by a low incidence of drowsiness. It possesses anticholinergic and antiemetic properties. The exact mechanism by which cyclizin (cyclizine hydrochloride, Valoid®) can prevent or suppress both nausea and vomiting from various causes is unknown. It increases lower oesophageal sphincter tone and reduces the sensitivity of the labyrinthine apparatus. It may inhibit the part of the midbrain known collectively as the emetic centre.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
5.42 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
VALOID
Preventing
VALOID
Preventing
VALOID

Cmax

ValueDoseCo-administeredAnalytePopulation
90 ng/mL
18.682 mg single, intravenous
CYCLIZINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
273.53 ng × h/mL
18.682 mg single, intravenous
CYCLIZINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
13.53 h
18.682 mg single, intravenous
CYCLIZINE plasma
Homo sapiens

Doses

AEs

Drug as perpetrator​

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
1 tablet (50 mg) orally, which may be repeated up to three times a day.
Route of Administration: Oral
In Vitro Use Guide
Cyclizine was tested for its effect on anti-IgE-induced histamine release from human lung fragments in vitro. IC50 value was 5.42 uM (0.14-20.44).